Description

Sporimune Oral Solution for Cats and Dogs - 25ml

Sporimune may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase Sporimune if you have or are in the process of arranging such a prescription. See information bar for further details.

Sporimune Oral Solution for Cats and Dogs is used for the treatment of chronic manifestations of atopic dermatitis in dogs. Sporimune is also used for the symptomatic treatment of chronic allergic dermatitis in cats.

Do not use Sporimune in cases of hypersensitivity to the active substance or any of the excipients. Do not use Sporimune in dogs less than six months of age or less than 2 kg in weight. Do not use Sporimune in cases with a history of malignant disorders or progressive malignant disorders. Do not vaccinate with a live vaccine during treatment with Sporimune or within a two-week interval before or after treatment.

Consideration should be given to the use of other measures and/or treatments to control moderate to severe pruritus when initiating therapy with Sporimune. Clinical signs of atopic dermatitis in dogs and allergic dermatitis in cats such as pruritus and skin inflammation are not specific for this disease. Therefore other causes of dermatitis such as ectoparasitic infestations, other allergies which cause dermatological signs (e.g. flea allergic dermatitis or food allergy) or bacterial and fungal infections should be evaluated and eliminated where possible. It is good practice to treat flea infestations before and during treatment of atopic and allergic dermatitis with Sporimune.

A complete clinical examination should be performed before treatment with Sporimune. Any infections should be properly treated before initiation of Sporimune treatment. Infections occurring during treatment are not necessarily a reason for drug withdrawal, unless the infection is severe. Particular attention must be paid to vaccination. Treatment with Sporimune may interfere with vaccination efficacy. In the case of inactivated vaccines, it is not recommended to vaccinate during treatment or within a two-week interval before or after administration of the product. It is not recommended to use other immunosuppressive agents concomitantly with Sporimune.

Closely monitor creatinine levels in dogs with severe renal insufficiency. Cats: Allergic dermatitis in cats can have various manifestations, including eosinophilic plaques, head and neck excoriation, symmetrical alopecia and/or miliary dermatitis. The immune status of the cats to FeLV and FIV infections should be assessed before treatment. Cats that are seronegative for T. gondii may be at risk of developing clinical toxoplasmosis if they become infected while under treatment. In rare cases this can be fatal. Potential exposure of seronegative cats or cats suspected to be seronagative to Toxoplasma should therefore be minimised (e.g. keep indoors, avoid raw meat or scavenging). Sporimune was shown to not increase T. gondii oocyte shedding in a controlled laboratory study. In cases of clinical toxoplasmosis or other serious systemic illness, stop treatment with ciclosporin and initiate appropriate therapy. Clinical studies in cats have shown that decreased appetite and weight loss may occur during Sporimune treatment. Monitoring of body weight is recommended. Significant reduction in body weight may result in hepatic lipidosis. If persistent, progressive weight loss occurs during treatment it is recommended to discontinue treatment until the cause has been identified.

The efficacy and safety of Sporimune has neither been assessed in cats less than 6 months of age nor weighing less than 2.3 kg. Special precautions to be taken by the person administering the veterinary medicinal product to animals: Accidental ingestion of this product may lead to nausea and/or vomiting. To avoid accidental ingestion, the product must be used and kept out of reach of children. Do not leave unattended filled syringe in the presence of children. Any uneaten medicated cat food must be disposed of immediately and the bowl washed thoroughly. In case of accidental ingestion, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the physician.

Sporimune can trigger hypersensitivity (allergic) reactions. People with known hypersensitivity to ciclosporin should avoid contact with the product. Irritation to eyes is unlikely. As precautionary measure avoid contact with eyes. In case of contact, rinse thoroughly with clean water. Wash hands and any exposed skin after use.

Shelf life after first opening the immediate packaging: 6 months Special precautions for storage: Do not refrigerate Sporimune. Store in the original container in order to protect from light. Sporimune contains fat components from natural origin which can become solid at lower temperatures. A turbidity or jelly-like formation may occur below 15°C which is however reversible at temperatures up to 25°C. However, this does not affect either the dosing nor the efficacy and safety of the product.

Legal category

Sporimune is a POM-V. Pet Prescription is Required